Veracyte, Inc. (VCYT)
Nasdaq: VCYT · Services-Medical Laboratories · South San Francisco, CA · filing with the SEC since 2006
Grade6.3
◀ Past 6.2● Present 6.6▶ Future 6.1
Who owns Veracyte, Inc.
As filed with the SECHolders of 5% or more
6
Blackrock, Inc. holds 15.2% of Common Stock, as its SCHEDULE 13G/A filed Aug 1, 2025 says.
Directors and officers
15
report now, of 29 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Aug 1, 2025 · Common Stock · 8.4% in Apr 17, 2025
Fmr LLC
SCHEDULE 13G/A · filed Jun 5, 2026 · COMMON STOCK · 9.7% in May 6, 2026
Artisan Partners Asset Management Inc.
SCHEDULE 13G/A · filed May 13, 2026 · Common Stock · 7.9% in Feb 3, 2026
State Street Corporation
SCHEDULE 13G · filed May 12, 2026 · COMMON STOCK · 5.3% in Nov 10, 2025
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
ARK Investment Management LLC
SCHEDULE 13G/A · filed Jan 8, 2026 · Common Stock · reported falling below 5%, from 5.68% in Nov 4, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What VCYT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
C2i Genomics, Inc.
A company bought · acquisition · Jan 2024 · owns, named in the 10-K filed Feb 26, 2026
C2i Inc
A company bought · acquisition · Jan 2024 · owns, named in the 10-K filed Feb 26, 2026
Nano String
A company bought · acquisition · Nov 2019 · owns, named in the 10-K filed Feb 26, 2026
8 subsidiaries in 4 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
61sales
0purchases
58sales on a scheduled plan
11people selling
$22.6Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 29, 2025 to Oct 29, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 29, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Stapley Marc | Chief Executive Officer | 5 | $8.9M | 5 | 0 | $0 |
| Eastham Karin | director | 7 | $2.2M | 7 | 0 | $0 |
| Jones Evan/ Fa | director | 7 | $2.0M | 7 | 0 | $0 |
| Chambers Rebecca | Chief Financial Officer | 9 | $1.9M | 9 | 0 | $0 |
| Mcguire Annie | EVP, General Counsel | 13 | $1.7M | 13 | 0 | $0 |
| Wygant Jonathan | VP, Chief Accounting Officer | 3 | $1.5M | 0 | 0 | $0 |
| Holstein Jens | director | 6 | $1.4M | 6 | 0 | $0 |
| Leite John | Global Chief Commercial Off | 5 | $1.2M | 5 | 0 | $0 |
| Febbo Phillip G. | Chief Scientific & Med Officer | 3 | $1.0M | 3 | 0 | $0 |
| Epstein Robert S | director | 1 | $400,000 | 1 | 0 | $0 |
| Bhanji Muna | director | 2 | $200,000 | 2 | 0 | $0 |